Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 123: CH505TF gp120 Manufacturing Comparison
NCT03856996Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2019
- Primary completion
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CH505TF gp120 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness, Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration and 4 more. Started May 2019; status: completed.
02
Drugs
CH505TF gp120
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03856996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856996.